EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Non‐Natural MUC1 Glycopeptide Homogeneous Cancer Vaccine with Enhanced Immunogenicity and Therapeutic Activity

Ana Guerreiro, Ismael Compañón, Foivos S Lazaris, Carlos Labão-Almeida, Paula Oroz, Mattia Ghirardello, Marta C Marques, Francisco Corzana iD, Gonçalo J L Bernardes iD

Angewandte Chemie International Edition · 02.12.2024 · 63 (49)

DOI: 10.1002/anie.202411009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 02.11.2024. Verfasst von Ana Guerreiro und 8 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisboa, Port…. Hauptthemen laut MEDLINE: Mucin-1, Cancer Vaccines, Glycopeptides. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Estatal de Investigación, Fundação para a Ciência e a Tecnologia, Horizon 2020 Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glycopeptides derived from the glycoprotein mucin‐1 (MUC1) have shown potential as tumor‐associated antigens for cancer vaccine development. However, their low immunogenicity and non‐selective conjugation to carriers present significant challenges for the clinical efficacy of MUC1‐based vaccines. Here, we introduce a novel vaccine candidate based on a structure‐guided design of an artificial antigen derived from MUC1 glycopeptide. This engineered antigen contains two non‐natural amino acids and has an α‐ S ‐glycosidic bond, where sulfur replaces the conventional oxygen atom linking the peptide backbone to the sugar N ‐acetylgalactosamine. The glycopeptide is then specifically conjugated to the immunogenic protein carrier CRM 197 (Cross‐Reactive Material 197), a protein approved for human use. Conjugation involves selective reduction and re‐bridging of a disulfide in CRM 197 , allowing the attachment of a single copy of MUC1. This strategy results in a chemically defined vaccine while maintaining both the structural integrity and immunogenicity of the protein carrier. The vaccine elicits a robust Th1‐like immune response in mice and generates antibodies capable of recognizing human cancer cells expressing tumor‐associated MUC1. When tested in mouse models of colon adenocarcinoma and pancreatic cancer, the vaccine is effective both as a prophylactic and therapeutic use, significantly delaying tumor growth. In therapeutic applications, improved outcomes were observed when the vaccine was combined with an anti‐programmed cell death protein 1 (anti‐PD‐1) checkpoint inhibitor. Our strategy reduces batch‐to‐batch variability and enhances both immunogenicity and therapeutic potential. This site‐specific approach disputes a prevailing dogma where glycoconjugate vaccines require multivalent display of antigens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucin-1Cancer VaccinesGlycopeptidesAnimalsHumansMiceCell Line, Tumor

Stichwörter der Autor:innen

AntigenCancerGlycoconjugateProtein modificationVaccine

Substanzen

Mucin-1Cancer VaccinesGlycopeptidesMUC1 protein, human

Autor:innen und Institutionen

  • Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisboa, Portugal.
  • Basinnov Lifesciences, Av. José Malhoa 2, Escritório 3.7, 1070-325, Lisboa, Portugal.
  • Departamento de Química and Instituto de Investigación en Química de la Universidad de La Rioja (IQUR), Madre de Dios, 53, 26006, Logroño, Spain.
  • Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW, Cambridge, UK.

ORCID-Profile: Francisco Corzana, Gonçalo J L Bernardes

Förderung

  • Agencia Estatal de Investigación
  • Fundação para a Ciência e a Tecnologia
  • Horizon 2020 Framework Programme

Zitieren

APA

Guerreiro, A., Compañón, I., Lazaris, F. S., Labão-Almeida, C., Oroz, P., Ghirardello, M., Marques, M. C., Corzana, F., & Bernardes, G. J. L. (2024). Non‐Natural MUC1 Glycopeptide Homogeneous Cancer Vaccine with Enhanced Immunogenicity and Therapeutic Activity. Angewandte Chemie International Edition, 63(49). https://doi.org/10.1002/anie.202411009

Vancouver

Guerreiro A, Compañón I, Lazaris FS, Labão-Almeida C, Oroz P, Ghirardello M, et al. Non‐Natural MUC1 Glycopeptide Homogeneous Cancer Vaccine with Enhanced Immunogenicity and Therapeutic Activity. Angewandte Chemie International Edition. 2024;63(49). doi:10.1002/anie.202411009

BibTeX
@article{Guerreiro2024,
  author = {Guerreiro, Ana and Compañón, Ismael and Lazaris, Foivos S and Labão-Almeida, Carlos and Oroz, Paula and Ghirardello, Mattia and Marques, Marta C and Corzana, Francisco and Bernardes, Gonçalo J L},
  title = {Non‐Natural MUC1 Glycopeptide Homogeneous Cancer Vaccine with Enhanced Immunogenicity and Therapeutic Activity},
  journal = {Angewandte Chemie International Edition},
  year = {2024},
  volume = {63},
  number = {49},
  doi = {10.1002/anie.202411009}
}
Kostenlos starten →